Post-earnings recap
Reported
Fri, Jan 30, 2026
EPS actual
$11.44
EPS est.
$8.28
EPS surprise
+38.18%
1-day move
-1.07%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Regeneron Pharmaceuticals reported strong earnings per share, exceeding expectations significantly. However, the stock fell by 1.07% in reaction to the lack of revenue data and guidance. Investors may be cautious due to the absence of future projections, despite the positive EPS surprise.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $11.44 | N/A | +38.18% |
Overall, management expressed confidence in their product pipeline and the company's ability to navigate market challenges. However, they acknowledged the competitive landscape.
Management highlighted strong performance in key products.
They emphasized ongoing investment in R&D to drive future growth.